Viewing Study NCT03948750


Ignite Creation Date: 2025-12-24 @ 4:54 PM
Ignite Modification Date: 2025-12-24 @ 4:54 PM
Study NCT ID: NCT03948750
Status: COMPLETED
Last Update Posted: 2019-05-14
First Post: 2019-05-10
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Immunoblotting and Goldmann-Witmer Coefficient for Ocular Toxoplasmosis
Sponsor: Hospices Civils de Lyon
Organization:

Study Overview

Official Title: Comparison of Immunoblotting (IgA and IgG) and the Goldmann-Witmer Coefficient for Diagnosis of Ocular Toxoplasmosis in Immunocompetent Patients
Status: COMPLETED
Status Verified Date: 2019-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: COPILOT
Brief Summary: Ocular toxoplasmosis (OT) is a common cause of posterior uveitis worldwide. The diagnosis of OT is based on clinical findings, but in most cases, laboratory tests are required to confirm the etiology, especially when other diseases are suspected. The aim of this study was to evaluate which methods, between the Goldmann-Witmer coefficient (GWC) and immunoblotting (IB) with both IgG and IgA, in aqueous humour (AH) samples, can be the most sensitive to diagnose OT, in current practice, especially in the first three weeks.
Detailed Description: Goldmann-Witmer coefficient (GWC): compares the levels of intraocular antibody (igG) production to that serum, as measured by ELISA.

GWC = (Level of specific IgG in aqueous humour/level of specific IgG in serum)/(Total IgG in aqueous humour/Total IgG in serum)

0.5 to 2: No intraocular antibody production, 2 to 4: Suggestive of intraocular antibody production, \> 4: Diagnostic of intraocular antibody production to a specific microbial pathogen

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: